Qantas has painted up its latest Boeing 737-800 in a special colour scheme inspired by the work of the late West Australian Indigenous painter Paddy Bedford.The plane, the airline’s 69th 737-800, is the fourth aircraft with Indigenous livery for Qantas, with over 20 years of Indigenous livery history.The concept is a joint initiative between Qantas, the family and estate of Paddy Bedford, Australian Indigenous design studio Balarinji and the National Gallery of AustraliaQantas will take members of Paddy Bedford’s family and community to Seattle next week to take delivery of this special aircraft.The 737-800 will arrive in Australia on November 11 and AirlineRatings.com will be on board the delivery flight.
In contrast to the fury and chaos of the recent Maratha quota protests, a day-long, State-wide agitation on Monday called by the Dhangar (shepherd) community demanding inclusion into the list of Scheduled Tribes (STs) passed off without incident.Barring traffic snarls at several places in Nagpur, Marathwada and parts of north Maharashtra, the agitation was largely peaceful, said police sources.However, Dhangar community leaders across the State warned of intensifying the agitation in the first week of September unless the Devendra Fadnavis government took a concrete step to resolve the long-pending issue. The agitation, under the banner of the Dhangar Sangharsh Samiti Maharashtra Rajya, received an enthusiastic response in Aurangabad, Nagpur, Solapur, Nanded and Jalgaon.“The Chief Minister has been putting us off with assurances. A meeting with him was held on August 10 and while the discussions were positive, he failed to clarify in how many days the State government would award the ST reservation to the community,” said Bharatiya Janata Party (BJP)’s Rajya Sabha MP, Dr. Vikas Mahatme, who staged a ‘chakka jam’ in Nagpur with several protestors. Dr. Mahatme, an ophthalmologist and Padma Shri recipient, had spearheaded the agitation before the BJP came to power in 2014. He, along with 25 agitators, was briefly detained by the Nagpur police.In Sangli’s Atpadi Taluk, bus services were suspended in the wake of the agitation, while in Kolhapur, a meeting of Dhangar community leaders condemned the BJP government for hoodwinking the community with false promises. “Since 2015, the BJP-ruled government has been assuring us of granting reservation. But after four years in power, they seem to have no intention in fulfilling their pre-election promise,” said a leader at the meeting. Earlier in the day, protesters burnt tyres and blocked the Jalna-Auranagabad road for several hours, holding up traffic. Likewise, the Nagpur-Wardha road was jammed for a while as agitators demonstrated with sheep and goats along the Ahmednagar-Manmad road.In Jalgaon, peaceful protests commenced at several areas in the district.Speaking in Ahmednagar, senior BJP leader Eknath Khadse, too, urged the State to expedite the process of including the Dhangar community in the ST list.The community, currently included in the Vimukta Jati and Nomadic Tribes category, is seeking a higher quota in the ST list.Dhangar leaders in Maharashtra contend that while their brethren, called ‘Dhangad’ in other parts of the country are availing of ST benefits, those in the State are denied these owing to a long-standing typographical error on the name.On Sunday, a youth in Parbhani district had allegedly committed suicide over the delay in granting reservation to the community, which has demanded that the BJP government fulfil its poll promise to include them in the ST category.Before the 2014 Assembly election, the BJP had lured some leaders from the community with promises of reservation. After the poll, it had inducted Mahadev Jankar, a prominent Dhangar leader and chief of the Rashtriya Samaj Paksha (RSP) and minor BJP ally, into the State cabinet as a sop to the community.It had also commissioned the Tata Institute of Social Sciences (TISS) to make a study on the backwardness of the community.Sharad Pawar’s Nationalist Congress Party (NCP) too had jumped into the fray to win the hearts and minds of the community by expressing support for the contentious Dhangar reservation issue. Bharipa Bahujan Mahasangh (BBM) chief Prakash Ambedkar, too, held a rally in Pandharpur in May this year in a bid to reach out to the community.
Share via Email Anthony Joshua has admitted Joseph Parker got under his skin with jibes about his supposed glass jaw and being “the king of steroids” – but said he will come in faster and lighter and make the New Zealander pay when they fight in March.Joshua, who puts his WBA, IBF and IBO belts on the line against Parker, wants to end the year as undisputed heavyweight champion – first by taking the New Zealander’s WBO belt and then by defeating the WBC champion, Deontay Wilder, in what he hopes will be a compelling summer unification fight at Wembley Stadium. He warned his rivals he has improved significantly after revamping his training following his below-par showing against Carlos Takam in October. Share on LinkedIn “I am leaps and bounds ahead compared to the Klitschko and Takam fights,” said Joshua, who pointed out his weight was already down to 17st 8lb, eight pounds lighter than against Takam. “I’m watching what I eat, running further and doing more than I did last year. Last week I did 20 rounds in the gym which I wasn’t even doing for Klitschko, and we’re still 11 weeks to the Parker fight.“I think speed is in power,” he added. “When you’re heavy and you try to club these durable fighters, it’s not that simple just to go ‘boom’. Just because I’m the most muscly man, it doesn’t mean I can just hit someone and knock them out. It’s the shot that you don’t see coming that knocks you out. When I’m quicker – bang, bang, bang – that’s when I can knock my opponents down a lot easier.”The 28-year-old had sharp words for Parker and his entourage, who he said had lied about him being put down in the gym and using performance-enhancing drugs to hype the fight and annoy him. “Three times it’s happened,” he said. “If you want to use it as a PR stunt carry on using it as a PR stunt, but let’s just talk about facts if you want to talk real. It gets under my skin. If he’s better than me, quicker than me, tougher than me, it will take a lot to put me away because I won’t stop coming.”Joshua pointed out he was not only tested regularly by UK Anti-Doping but also paid extra to be on the Voluntary Anti-Doping Association testing programme before fights. “I give them a slot and they can turn up anywhere, if I’m on holiday, at a hotel, at a club,” he said. “I just text them and say I’m going to be here. You have to let them know. I normally give them the time when I’m going to be in the gym training for the opportunity.” Deontay Wilder: ‘I want to fight Anthony Joshua, but Eddie Hearn doesn’t want to risk his gravy train’ Anthony Joshua dismisses glass jaw jibes by Joseph Parker team as ‘fake news’ Support The Guardian Share on Pinterest … we have a small favour to ask. More people, like you, are reading and supporting the Guardian’s independent, investigative journalism than ever before. And unlike many news organisations, we made the choice to keep our reporting open for all, regardless of where they live or what they can afford to pay.The Guardian will engage with the most critical issues of our time – from the escalating climate catastrophe to widespread inequality to the influence of big tech on our lives. At a time when factual information is a necessity, we believe that each of us, around the world, deserves access to accurate reporting with integrity at its heart.Our editorial independence means we set our own agenda and voice our own opinions. Guardian journalism is free from commercial and political bias and not influenced by billionaire owners or shareholders. This means we can give a voice to those less heard, explore where others turn away, and rigorously challenge those in power.We hope you will consider supporting us today. We need your support to keep delivering quality journalism that’s open and independent. Every reader contribution, however big or small, is so valuable. Support The Guardian from as little as $1 – and it only takes a minute. Thank you. Reuse this content Share on Twitter Boxing The Observer Since you’re here… Share on Messenger Share on Facebook Share on WhatsApp Anthony Joshua On one occasion the drug testers even accompanied him to Nando’s in Sheffield. “You have to go through the piss test before they take your blood,” Joshua explained. “So I said: ‘Look, I haven’t eaten, I’m not going to sit here for an hour.’ So they have to follow me, I got in my car. We went to eat at Nando’s. They were patient. Then they followed me home.”Meanwhile Joshua’s promoter, Eddie Hearn, has told Wilder he must be realistic if he wants a unification fight against Joshua. “We were up for fighting Wilder now,” he said. “But it’s very easy to kill a fight. And you kill a fight by coming out with an unrealistic remark like: ‘I won’t take one per cent less than 50-50 or there’s no fight.’ We look at that and say: ‘Mate go away, don’t waste our time.’ We would love Wilder to be next but he’s got delusions of grandeur.”Before that Joshua knows he will have to get past Parker – who clearly believes he can spring a huge upset. “I played rugby union when I was at school for three years as a lock, as you can probably tell by my cauliflower ear,” Parker said. “I had thoughts of turning professional at rugby but my dad always told me to focus on one sport so I chose boxing. And it was the best decision ever.”However, Joshua intends to make him eat those words – and plenty of others – on 31 March. Read more news Topics Read more
About the authorPaul VegasShare the loveHave your say Tottenham legend Ardiles insists title push remains onby Paul Vegasa month agoSend to a friendShare the loveTottenham legend Ossie Ardiles insists a title push remains on.Tottenham are third in the Premier League table after five matches, just two points behind Manchester City but seven adrift of leaders Liverpool.”[It’s been] very positive. I believe that there are two teams to beat – Liverpool and Manchester City – but I think we are one of the teams that can beat them and we are going to try and fight with them all the way,” Ardiles told Sky Sports.”We have a very, very strong squad. That showed last season and in the Champions League as well. “We do have a very strong squad but we have to be a little bit better and I hope we will do it this year.”
Jim Harbaugh was only Michigan’s head coach for one of the program’s three rivalry contests against Ohio State during Ezekiel Elliott’s tenure, but he seems to have made quite an impression on the star running back. Friday, Elliott, who is going through the ESPN car wash today, trashed Harbaugh, telling Paul Finebaum that he’s “tired” of hearing about him. Elliott also called out Harbaugh for talking smack when he hasn’t won a rivalry game. Yikes.“I’m tired of hearing about Coach Harbaugh he needs to get in check with reality” – @EzekielElliott pic.twitter.com/QHElXCl7QV— Paul Finebaum (@finebaum) April 15, 2016more from @EzekielElliott: “you can’t talk smack about a rivalry when you haven’t won a game. You have to win ballgames to talk behind it.”— Paul Finebaum (@finebaum) April 15, 2016Here’s @EzekielElliott‘s full quote about Jim Harbaugh on @finebaum pic.twitter.com/FkeSmMrqZa— John Hayes (@johnP_hayes) April 15, 2016This isn’t exactly a surprise – Elliott has made a living off of trolling Michigan the past few years. But it’s still hilarious, and reminds us that there is no better college football rivalry than Ohio State vs. Michigan.
Teleste will use IBC to highlight its IP over coax solutions.Teleste says it will highlight the advantages of bringing fibre connections to an apartment building (FttB) and utilizing existing coaxial cables for enabling IP delivery to individual apartments, enabling the cost of building fibre level broadband connections to be reduced to one fifth compared to using fibre all the way.Products on show include the DOCSIS Access Hub DAH, which provides a solution for introducing high-speed broadband connections to coaxial cable networks and extend IP network inside apartment buildings and hotels by utilising existing coaxial cable infrastructure.The product includes advanced management tools allowing free capacity allocation, 16 downstream and four upstream channels, QAM64, QAM256, QAM1024 downstream support, QPSK, QAM16, QAM64, QAM256 upstream support, a capacity of 960Mbps downstream and 160 Mbps upstream, remote configuration and management, integrated power supply, amplifier and level 2 switch, Optical interface SFP slot, Ethernet 2xGbE copper and Coax PG11, and encapsulation class IP54Teleste will exhibit at IBC on stand 4.B77
YouTube Red, the Google-owned video site’s paid offering, will launched in multiple markets internationally this year, according to chief business officer Robert Kyncl.Robert KynclKyncl, interviewed by French financial daily Les Echos, said that YouTube’s deal with Univeral Music last month gave it the licenses to distribute the Universal Music catalogue on both a free and pay basis globally.Kyncl said that while YouTube did not have a specific launch date penned in for France, this was a market that was “important for us”.Kyncl’s comments came as YouTube renewed agreements with French copyright collecting agencies SACD and ADAGP, enabling authors represented by the pair to continue to receive remuneration for the exploitation of their intellectual property by YouTube content creators.Google has also been in talks with music rights collecting agency SACEM. Kyncl said that other agreements would follow soon.Kyncl confirmed that YouTube was looking at “a better segmentation” of music and video on YouTube Red, which currently offers the entirety of YouTube content on an ad-free basis for a US$10 monthly fee, which could enable it to better compete with the likes of Spotify in international markets.However, he said that it was “not too late” to launch a product like the existing YouTube Red service internationally in a market that still had plenty of scope to develop.He said that the channel bouquets currently offered as part of YouTube Red in the US would not “for the time being” be offered elsewhere.In terms of original content, Kyncl said that YouTube would continue to focus on investing in talent that had developed a following on the platform. Investing in this talent produced an average increase in audience of about 30%, he said.Kyncl said that “more and more people are becoming video content creators” and compared the evolution of user-generated video to the way that digital photography had unleashed a wave of photographic creativity on the part of general user that had eclipsed professional photography’s share of the market.
In July 2018, the FDA granted an Emergency Use Authorization (EUA) for the DoD’s emergency use of Pathogen-Reduced Leukocyte-Depleted Freeze-Dried Plasma manufactured by the Centre de Transfusion Sanguine des Armées (often referred to as French freeze-dried Plasma). That action reflected the importance that both the DoD and the FDA place on efficiently prioritizing and expediting availability of potentially life-saving biological products that are essential to the urgent care of military personnel, especially those in potential battlefield settings. Granting this authorization supported access to this important product and ensures that it will be available if needed. In July 2018, the FDA approved the atropine autoinjector device as a medical countermeasure for chemical nerve agent exposure. This drug-device product was developed in partnership with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, and was approved six months ahead of the DoD’s product development schedule. In August 2018, following a priority review, the FDA approved the first prophylactic drug for malaria in over 18 years, tafenoquine (Arakoda). This drug was developed in partnership with the U.S. Army Medical Research and Materiel Command. On October 29, 2018, the FDA issued draft guidance to help foster the development and eventual approval of dried plasma products. Since these types of plasma products do not need to be stored frozen and can be reconstituted and administered quickly they can be used by military personnel in remote areas without freezers and other support equipment. Reviewed by James Ives, M.Psych. (Editor)Nov 5 2018Today, the U.S. Food and Drug Administration and the Department of Defense’s (DoD) Office of Health Affairs signed a Memorandum of Understanding regarding medical product development and assessment. This builds upon the work of both agencies to foster and prioritize the efficient development of safe and effective medical products intended to save the lives of American service members.”We’re extremely grateful to the men and women who defend our nation, often at great personal risk and sacrifice. It’s our honor and duty to support our military personnel by ensuring they have access to safe and effective medical products – especially products that meet the unique needs and settings in which soldiers may require medical treatment,” said FDA Commissioner Scott Gottlieb, M.D. “The FDA has already been working closely with the DoD to identify opportunities to expedite availability of medical products, particularly those products used to treat injuries in battlefield settings. For example, as noted below, the Emergency Use Authorization for French freeze-dried plasma that was issued earlier this year. Our close collaboration with DoD has helped us target and more efficiently address DoD’s immediate product priorities and foster development and review of these products in the most streamlined manner possible. We are looking forward to additional partnership opportunities under the MOU.”The MOU formally establishes the framework under which the DoD and the FDA will implement the law passed by Congress in 2017 for enhanced engagements between the DoD and the FDA. Under the terms of this MOU, the FDA will work closely with the DoD to evaluate how best to foster access to safe and effective medical products that serve the military’s medical needs; give the highest level of attention to and expedite review of priority DoD medical products; provide ongoing technical advice to aid in the rapid development and manufacturing of medical products for use by the military; and examine products currently under development to determine opportunities to streamline review and expedite their availability. The 2017 law also expanded the FDA’s authority to authorize emergency uses of medical products to reduce deaths and severity of injuries caused by chemical, biological, radiological or nuclear (CBRN) agents or agents that may cause, or are otherwise associated with, an imminently life-threatening and specific risk to the U.S. military forces and for other purposes.”This MOU furthers the existing partnership between the Department of Defense and the FDA to equip our military with the best and most innovative military medical support possible,” said Terry M. Rauch, Ph.D., M.P.H., M.B.A., Acting Deputy Assistant Secretary of Defense, Health Readiness Policy & Oversight, DOD. “Our servicemen and women risk their lives protecting our country. Today’s MOU reflects the commitment of the DoD and the FDA to ensure timely access to life-saving medical products for U.S. troops and to continue fostering the development of new innovative medical products that can help ensure the operational readiness of American troops. We look forward to continuing to work with the FDA as we analyze and implement measures to provide the best possible medical products and care to all military personnel – on the battlefield, stationed around the world and at home.””Our enhanced collaboration with our DoD partners has been vital to gaining a better understanding of the health needs of those protecting our country,” said Anna Abram, the FDA’s Deputy Commissioner for Policy, Planning, Legislation and Analysis. “Today’s MOU is a key milestone in implementing a robust and enduring pathway that fulfills our commitment to expedite access to safe and effective medical products for our military personnel.”Related StoriesResearchers improve training modules for future surgeons with 3D printingDisrupting ChIP Assay Technology with New AdvancementsSociologist identifies link between decline in stable manufacturing jobs and reduced fertility ratesThe MOU signed today builds upon the approach that the FDA outlined in 2018 to advance the development and availability of medical products to help save the lives of American military personnel in a work plan developed in close collaboration with the DoD. The MOU reflects the agency’s commitment to working to address the medical needs of military personnel, especially by helping to expedite the development and review of medical products that are a priority for the DoD and to aid in the rapid development and manufacturing of safe and effective medical products for use by the U.S. military. Specifically, the MOU sets forth a framework to implement the 2017 law, which included provisions to allow the Secretary of Defense to request, and the FDA to take, specific actions to expedite the development of medical products, and the review of investigational submissions, applications for approval/licensure, and submissions/notifications for clearance for such medical products to diagnose, prevent, treat or mitigate a specific and life-threatening risk to the U.S.As part of the ongoing and frequent collaborations between the FDA and the DoD, additional steps taken over the past several months include: The FDA and the DoD are committed to the ongoing partnership and are confident that today’s MOU will enhance those efforts to better serve the health care needs of American military personnel.The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products. Source:https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm624970.htm
According to the CDC, nearly 40 percent of Americans, 93 million people, are obese, and even more are overweight.For more information and complete survey results, go to: clevelandclinic.org/loveyourheartMethodologyCleveland Clinic’s survey of the general population gathered insights into Americans’ perceptions of heart health and weight. This was an online survey conducted among a national probability sample consisting of 1,002 adults 18 years of age and older, living in the continental United States. The total sample data is nationally representative based on age, gender, ethnicity and educational attainment census data. The online survey was conducted by Research Now and completed between September 20 and September 28, 2018. The margin of error for the total sample at the 95% confidence level is +/- 3.1 percentage points. Source:https://my.clevelandclinic.org/ Reviewed by James Ives, M.Psych. (Editor)Jan 31 2019A Cleveland Clinic survey finds that while most Americans (88 percent) understand that there is a connection between a healthy heart and a healthy weight, most aren’t doing enough – or anything – to combat their own weight issues. The survey found 74 percent are concerned about their weight and 65 percent are worried about getting heart disease due to extra pounds, yet less than half (43 percent) of Americans have tried to make dietary changes to lose weight and 40 percent of those who describe themselves as overweight or obese say they aren’t careful about which foods they eat.Part of the problem may be that Americans aren’t sure what to eat for heart health. Nearly one-in-five (18 percent) believe their diet has nothing to do with their heart health, and a mere 14 percent knew that a Mediterranean diet is healthiest for heart health. What’s more, nearly half of Americans (46 percent) believe using artificial sweeteners is a healthy way to lose weight despite studies showing they don’t promote weight loss.The survey also revealed Americans don’t fully understand the impact excess weight has on their heart and overall health. The overwhelming majority of Americans (87 percent) fail to link obesity to cancer or atrial fibrillation (80 percent). More than half of Americans also don’t know that obesity is linked to high “bad” cholesterol levels (54 percent) or coronary artery disease (57 percent) and two-thirds (64 percent) don’t know it can lead to a stroke.”Most Americans understand abstractly that being overweight or obese is not good for your health, but it seems we are not grasping that the leading causes of death and disability – stroke, cancer, coronary artery disease – are all adversely affected by increased weight,” said Steven Nissen, M.D., chairman of Cardiovascular Medicine at Cleveland Clinic. “We need to do a better job of educating patients and the public about the major consequences of carrying excess weight and the benefits of losing weight. A patient only needs to lose five percent of their body weight to start seeing important health benefits.”Eighty-four percent of Americans say they have tried at least one weight-loss method in the past. About one-third (30 percent) say they typically stick with it between one week and one month. Americans cite dislike of exercise (24 percent) and lack of time (22 percent) as their main barriers to maintaining a healthy weight. Most Americans also believe their metabolism is detrimental to weight loss – 60 percent of women and 46 percent of men say their metabolism is working against them.”Americans may be correct that their metabolism is thwarting their weight loss efforts,” said Dr. Nissen. “Once you’ve been overweight, your body tries to hold on to that excess fat, making it more difficult to lose weight. It’s best to work with your physician to develop a steady long term weight loss plan that will help you keep off the pounds. Quick weight loss programs are not effective.”Related StoriesSmoking triples the risk of death from cardiovascular diseaseImplanted device uses microcurrent to exercise heart muscle in cardiomyopathy patientsWeightlifting is better for the heart than cardioHeart disease is the No. 1 cause of death in the United States and around the world. The survey was conducted as part of Cleveland Clinic’s “Love your Heart” consumer education campaign in celebration of American Heart Month. Cleveland Clinic has been ranked the No. 1 hospital in the country for cardiology and cardiac surgery for 24 years in a row by US News & World Report.Additional survey findings include: All fat is not created equal: When it comes to body shapes, almost half (45%) falsely believe that all types of fat put you at equal risk for heart disease; however, numerous studies have shown that fat stored in the abdomen is the most dangerous. Not feeling the pressure: Most Americans say they are concerned about a family member’s weight (62 percent), or them getting heart disease due to their weight (64%). However, for many, outside pressure to lose the weight doesn’t help. Fifty-seven percent say they don’t need others to tell them to lose weight because they already know they should. Baby Boomers (65 percent) are particularly resistant to others weighing in on their weight. Seeking medical advice: While 44 percent of Americans say they are most likely to turn to their physician for nutrition advice, only a quarter (28 percent) have told their doctor they’d like to lose weight. Even less (22 percent) say they’ve discussed heart health in relation to their weight with their doctor.
Reviewed by James Ives, M.Psych. (Editor)Mar 29 2019A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.The investigators found that in addition to its known ability to block the production of cell growth compounds, the drug DFMO (difluoromethylornithine) acts directly on the bacterium Helicobacter pylori to reduce its virulence. H. pylori infection is the primary cause of gastric cancer.The findings, reported in the March 12 issue of Proceedings of the National Academy of Sciences, support further studies of DFMO for the prevention of stomach cancer, the third leading cause of cancer deaths worldwide.H. pylori infects the stomachs of half of the human population, but only about 1 percent of infected individuals develop stomach cancer. Although it’s possible to treat the infection to prevent stomach cancer, it’s not clear whom to treat. Plus, the bug may be conferring beneficial effects — esophageal reflux diseases, asthma and other allergic disorders occur more frequently in people who are not infected with H. pylori.”H. pylori has co-evolved with humans for at least 60,000 years, probably longer, and attempting to prevent stomach cancer by eliminating the infection with widespread use of antibiotics is not necessarily a good idea,” said Keith Wilson, MD, Thomas F. Frist Sr. Professor of Medicine and professor of Pathology, Microbiology and Immunology.”Our study suggests that it might be possible to reduce the virulence of the bacteria, without having to eliminate it. It’s a speculative and unusual way to think about an infection, but it could be an interesting strategy.”Wilson, who also directs the Vanderbilt Center for Mucosal Inflammation and Cancer, and his team previously linked the production of cell growth compounds called polyamines to the development of stomach cancer in an H. pylori-infected animal model. They demonstrated that treatment of the animals with DFMO, which inhibits an enzyme that is key to the production of polyamines, prevents stomach cancer.Related StoriesCancer killing capability of lesser-known immune cells identifiedSpecial blood test may predict relapse risk for breast cancer patientsStudy reveals link between inflammatory diet and colorectal cancer riskTheir findings are the basis for an ongoing clinical trial of DFMO for stomach cancer prevention in Honduras and Puerto Rico.Patients with pre-malignant lesions in the stomach, as determined by endoscopy, are enrolled in the trial of DFMO and will be studied for disease progression.To further explore how DFMO works, J. Carolina Sierra, PhD, research instructor in Medicine, collected H. pyloribacteria from infected animals that had been treated (or not) with DFMO. Using an in vitro test, she assessed the activity of one of the main H. pylori virulence factors, a protein called CagA. CagA is “injected” into stomach epithelial cells, where it contributes to oncogenic signaling pathways.”What we noticed is that bacterial strains coming from DFMO-treated animals have reduced ability to move this virulence factor into epithelial cells,” Sierra said.The researchers discovered that DFMO treatment — in animals or in vitro — caused mutations in the H. pylori gene that encodes CagY, part of the translocation machinery that injects CagA into cells.They demonstrated that animals infected with H. pylori strains containing mutations in the CagY gene did not develop stomach cancer.This finding, Wilson said, supports using DFMO or other tools to reduce H. pylori virulence for cancer prevention.”This drug (DFMO), which inhibits a very specific enzymatic pathway, also has what some might call ‘off target’ effects: it causes mutations in an H. pylori gene that affects the translocation of CagA,” Wilson said. “The vast majority of gastric cancer is associated with strains that are CagA-positive. If this drug interferes with CagA activity, that’s an added bonus.”The investigators will analyze H. pylori strains isolated from the DFMO trial participants in Honduras and Puerto Rico to determine if there is a similar reduction of bacterial virulence in people.Source: http://news.vumc.org/2019/03/28/cancer-prevention-drug-disables-h-pylori/